VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
VERAXA Biotech appointed Christoph Erkel, Ph.D., as Chief Scientific Officer, promoting him from Vice President of Research & Development effective immediately. Erkel succeeds Rick Austin, Ph.D., who departs after a transition period, bringing 20 years of antibody therapeutic expertise to lead the company's BiTAC platform development.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.